<DOC>
	<DOCNO>NCT00530309</DOCNO>
	<brief_summary>A Phase I/II study investigate safety , pharmacokinetics pharmacodynamics GSK716155 Japanese subject type 2 diabetes mellitus</brief_summary>
	<brief_title>Clinical Assessment GSK716155 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus diagnose least 3 month FPG level &lt; =240mg/dL HbA1c 6.5 % 10 % inclusive . Must diet control OR take single oral antidiabetic agent ( thiazolidinediones ) willing withdraw treatment 2 week prior study . Must BMI : &lt; =35kg/m2 , 20 70 year age inclusive . Woman must nonchildbearing potential . Exclusion criterion : Positive test result either syphilis , HBs antigen , HCV antibody , HIV antigen/antibody , HTLV1 antibody . Clinically significant hepatic enzyme elevation . History metabolic disease T2DM . Previous use insulin treatment diabetes within 3 month . History severe gastrointestinal disease . Clinically significant cardiovascular disease . Significant renal disease define screen lab test . History drug ( include albumin albumin contain agent ) allergy . History alcohol drug abuse . Donation blood excess 400mL within previous 4 month . Previously receive GLP1 mimetic albumincontaining product .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>type 2 diabeted mellitus</keyword>
	<keyword>safety</keyword>
	<keyword>GSK716155</keyword>
	<keyword>GLP-1 receptor agonist</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>